Immunostimulants drugs - versus control - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.80 [0.25, 2.53]< 19%5 studies (5/-)65.1 %lownot evaluable highcrucial-
deaths 0.39 [0.14, 1.08]< 122%9 studies (9/-)96.5 %lownot evaluable highcrucial-
hospitalization or death 0.36 [0.23, 0.55]< 164%10 studies (10/-)100.0 %lowcritical highcrucial-
clinical deterioration 0.24 [0.10, 0.56]< 10%1 study (1/-)100.0 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.50 [1.30, 1.74]> 10%1 study (1/-)100.0 %NAnot evaluable important-
hospitalization 0.61 [0.38, 0.97]< 171%6 studies (6/-)98.2 %lowserious highimportant-
mechanical ventilation 1.49 [0.25, 9.02]< 10%1 study (1/-)33.2 %NAnot evaluable important-
Recovery (time to event analysis only) 1.50 [1.30, 1.74]> 10%1 study (1/-)100.0 %NAnot evaluable important-
symptomatic Covid-19 0.56 [0.31, 1.00]< 10%1 study (1/-)97.6 %NAnot evaluable important-
viral clearance 1.08 [0.45, 2.60]> 172%2 studies (2/-)56.6 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.03 [0.42, 2.52]> 179%4 studies (4/-)52.5 %lownot evaluable highimportant-

safety endpoints 00

emergent treatment-resistant variants 0.64 [0.08, 4.94]< 167%2 studies (2/-)66.3 %some concernnot evaluable moderateimportant-
serious adverse events 0.25 [0.03, 2.23]< 10%1 study (1/-)89.2 %NAnot evaluable important-
adverse events 0.73 [0.44, 1.20]< 171%2 studies (2/-)89.2 %lownot evaluable highnon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.